-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

Benzinga·12/03/2025 13:41:20
Listen to the news
Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.